These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20015399)

  • 21. Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection.
    Shen H; Hyrc KL; Goldberg MP
    Neurobiol Dis; 2013 Nov; 59():69-79. PubMed ID: 23892229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease.
    Vande Velde C; Garcia ML; Yin X; Trapp BD; Cleveland DW
    Neuromolecular Med; 2004; 5(3):193-203. PubMed ID: 15626820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stable inheritance of an 85-kb triplication in C57BL/WldS mice.
    Mi W; Glass JD; Coleman MP
    Mutat Res; 2003 May; 526(1-2):33-7. PubMed ID: 12714180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration.
    Avery MA; Sheehan AE; Kerr KS; Wang J; Freeman MR
    J Cell Biol; 2009 Feb; 184(4):501-13. PubMed ID: 19237597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prion disease development in slow Wallerian degeneration (Wld(S)) mice.
    Gültner S; Laue M; Riemer C; Heise I; Baier M
    Neurosci Lett; 2009 Jun; 456(2):93-8. PubMed ID: 19429141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing expression of NAD+ synthesizing enzyme NMNAT1 does not affect the rate of Wallerian degeneration.
    Conforti L; Janeckova L; Wagner D; Mazzola F; Cialabrini L; Di Stefano M; Orsomando G; Magni G; Bendotti C; Smyth N; Coleman M
    FEBS J; 2011 Aug; 278(15):2666-79. PubMed ID: 21615689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resveratrol abolishes resistance to axonal degeneration in slow Wallerian degeneration (WldS) mice: activation of SIRT2, an NAD-dependent tubulin deacetylase.
    Suzuki K; Koike T
    Biochem Biophys Res Commun; 2007 Aug; 359(3):665-71. PubMed ID: 17560549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity.
    Antenor-Dorsey JA; O'Malley KL
    Mol Neurodegener; 2012 Feb; 7():5. PubMed ID: 22315973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wallerian degeneration, wld(s), and nmnat.
    Coleman MP; Freeman MR
    Annu Rev Neurosci; 2010; 33():245-67. PubMed ID: 20345246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered brain metabolism in the C57BL/Wld mouse strain detected by magnetic resonance spectroscopy: association with delayed Wallerian degeneration?
    Tsao JW; Paramananthan N; Parkes HG; Dunn JF
    J Neurol Sci; 1999 Sep; 168(1):1-12. PubMed ID: 10500267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axotomy-dependent and -independent synapse elimination in organ cultures of Wld(s) mutant mouse skeletal muscle.
    Parson SH; Ribchester RR; Davie N; Gandhi NP; Malik RQ; Gillingwater TH; Thomson D
    J Neurosci Res; 2004 Apr; 76(1):64-75. PubMed ID: 15048930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection after transient global cerebral ischemia in Wld(s) mutant mice.
    Gillingwater TH; Haley JE; Ribchester RR; Horsburgh K
    J Cereb Blood Flow Metab; 2004 Jan; 24(1):62-6. PubMed ID: 14688617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy.
    Adalbert R; Nógrádi A; Szabó A; Coleman MP
    Eur J Neurosci; 2006 Oct; 24(8):2163-8. PubMed ID: 17074042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a critical site in Wld(s): essential for Nmnat enzyme activity and axon-protective function.
    Jia H; Yan T; Feng Y; Zeng C; Shi X; Zhai Q
    Neurosci Lett; 2007 Feb; 413(1):46-51. PubMed ID: 17207927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau-mediated axonal degeneration is prevented by activation of the Wld
    Stubbs K; Batchelor B; Sivanantharajah L; Sealey M; Ramirez-Moreno M; Ruiz E; Richardson B; Perry VH; Newman TA; Mudher A
    Brain Commun; 2023; 5(2):fcad052. PubMed ID: 37013175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Wallerian degeneration slow (Wld(s)) gene does not attenuate disease in a mouse model of spinal muscular atrophy.
    Rose FF; Meehan PW; Coady TH; Garcia VB; Garcia ML; Lorson CL
    Biochem Biophys Res Commun; 2008 Oct; 375(1):119-23. PubMed ID: 18680723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy.
    Samsam M; Mi W; Wessig C; Zielasek J; Toyka KV; Coleman MP; Martini R
    J Neurosci; 2003 Apr; 23(7):2833-9. PubMed ID: 12684470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotection by Wld
    Risner ML; Pasini S; McGrady NR; D'Alessandro KB; Yao V; Cooper ML; Calkins DJ
    Mol Neurodegener; 2021 Jun; 16(1):36. PubMed ID: 34090501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A local mechanism mediates NAD-dependent protection of axon degeneration.
    Wang J; Zhai Q; Chen Y; Lin E; Gu W; McBurney MW; He Z
    J Cell Biol; 2005 Aug; 170(3):349-55. PubMed ID: 16043516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The cellular distribution of the Wld s chimeric protein and its constituent proteins in the CNS.
    Fang C; Bernardes-Silva M; Coleman MP; Perry VH
    Neuroscience; 2005; 135(4):1107-18. PubMed ID: 16154290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.